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challenge. Moreover, insight into the different stages of he-
patocarcinogenesis can be possible with MRI. Despite its 
limited availability in some countries, it has to be rendered 
to be the modality of choice for the distinct evaluation of the 
cirrhotic liver.  Copyright © 2009 S. Karger AG, Basel 
 Introduction 
 Hepatocellular carcinoma (HCC) is among the most 
frequent tumors worldwide with an incidence rate of 20–
150/100,000/year in high-risk areas in Asia and Africa, of 
5–20/100,000/year in the areas with intermediate risk in 
Japan and the Mediterranean countries and of 5/100,000 
and less in areas with low risk in Northern Europe and 
the USA  [1] . One of the major risk factors for the develop-
ment of HCC is chronic hepatitis B and C and chronic 
alcohol abuse, especially if liver cirrhosis is already pres-
ent. In case of underlying liver cirrhosis, a stepwise devel-
opment of carcinogenesis from areas of regeneration to 
overt HCC has been described. According to this con-
cept, the most common terminology of the International 
Working Party of the World Congress of Gastroenterol-
ogy defined regenerative nodules, low-grade dysplastic 
nodules, high-grade dysplastic nodules and well-differ-
entiated HCC as steps from regeneration to cancer  [2–4] . 
However, also a de novo development of HCC takes place 
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 Abstract 
 Hepatocellular carcinoma (HCC) is a very frequent tumor 
worldwide. Its incidence is linked to the distribution of liver 
cirrhosis and viral hepatitis, which are the main risk factors 
for the development of HCC. For the evaluation of the cir-
rhotic liver and for the diagnosis of HCC, multidetector com-
puted tomography (MDCT) proved to be a robust and reli-
able tool. In MDCT the diagnosis of HCC can be made based 
on neovascularization with increased arterial and decreased 
portal venous supply. With modern magnetic resonance im-
aging (MRI), spatial resolution and robustness increased 
 dramatically. Beside the evaluation of neovascularization
by means of gadolinium-enhanced early dynamic MRI, the 
main advantages of MRI are additional information on tis-
sue composition and liver-specific function. With diffusion-
weighted imaging or plain T 1 - and T 2 -weighted sequences, 
different tissue elements like fat, hemorrhage, glycogen, 
edema and cellular density can be evaluated. Liver-specific 
contrast agents give insight into the Kupffer cell density or 
the hepatocellular function. The integration of all these parts 
into the MR examination allows for a very high detection rate 
for overt HCC nowadays, although very small HCCs are still a 
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 [2] . The challenge for the gastroenterologist, hepatic sur-
geon and radiologist is to detect premalignant and malig-
nant lesions early, to distinguish between the different 
regenerative nodules and HCC in patients with liver cir-
rhosis and to allocate the patients with HCC properly to 
the treatment options which are nowadays available.
 Computed Tomography 
 Computed tomography (CT) has developed dramati-
cally with the introduction of the multidetector technol-
ogy (MDCT). Especially the abdomen, where motion ar-
tifacts due to respiratory motion and bowel peristalsis are 
disturbing, takes great advantage from this technique.
 Adequate examination technique is critical for sensi-
tive detection of HCC. A triphasic examination of the 
liver with a plain, a late-arterial (arterial-dominant) and 
a portovenous phase scan can be regarded as standard 
today. The value of delayed scans (e.g. 3–5 min after con-
trast agent injection) to depict pathological tumor wash-
out has been demonstrated in the literature  [5] . With the 
short acquisition times of MDCT, contrast agent timing 
has become critical, since the optimal enhancement 
phase has to be included within a very short acquisition 
window. Therefore, the use of modern contrast agent 
power injectors and bolus timing is mandatory  [6] . De-
pending on the iodine concentration, fast flow rates up to 
5 or 6 ml/s are recommended  [6] . The dosing of the con-
trast agent should be related to the body weight with 1.5–
2 ml/kg b.w. (for a concentration of 300 mg iodine/ml)  [7] . 
The delay between reaching the triggering threshold of 
100 HU in the aorta and starting the scan is usually 15 s 
for the late-arterial (or arterial-dominant) phase. The op-
timal slice thickness of reconstructed CT images of the 
liver is still under debate. Past publications have been 
quite restricted here and recommended that the slice 
thickness should not be  ! 5 mm for the low-contrast or-
gan liver  [8, 9] . Recent publications, however, disocvered 
advantages for a reconstructed slice thickness down to
3 mm  [10] . If the slice thickness is further decreased, im-
age noise and low contrast overwhelm the positive effect 
of geometrical resolution. This phenomenon might only 
be covered with inadequately high radiation doses.
 For imaging of HCC and lesions in the cirrhotic liver 
the main diagnostic criterion in CT is the depiction of 
changes in the vascular supply of liver nodules due to 
neoangiogenesis as described for CT during hepatic an-
giography (CTHA) by Matsui  [4] . In addition to the in-
trahepatic staging with regard to number and size of 
HCC lesions, complicating factors like liver cirrhosis and 
patency of the portal vein are also of relevance for assign-
ing patients to a proper treatment regimen.
 In case of intravenous contrast application, HCC typ-
ically presents as a hyperdense lesion in the arterial-dom-
inant phase with following washout to iso- or mostly hy-
podensity in the portovenous phase ( fig. 1 ). The presence 
of pathological washout can be depicted with higher ac-
curacy in delayed phases  [5, 11] . This is of importance 
since both the presence of hypervascularity and patho-
logical washout with one or two imaging techniques in 
lesions ranging from 1 to 2 cm and  1 2 cm, respectively, 
allows the definite diagnosis of a HCC non-invasively ac-
cording to the EASL-AASLD practice guidelines  [12] . In 
CT the depiction of these vascular changes is crucial 
since there are no other reliable criteria to detect or char-
acterize HCC ( fig. 2 ). The lack of additional criteria is the 
main reason for false-positive findings (e.g. arteriove-
nous shunts, dysplastic nodules with pathological vascu-
larization) or false-negative findings (e.g. well-differenti-
ated HCC without arterial hyperenhancement, hypovas-
cular HCC). From a radiological/pathological aspect, the 
a b
 Fig. 1. CT scan of a 62-year-old female pa-
tient with liver cirrhosis Child-Pugh A 
based on a chronic hepatitis C. In liver seg-
ment VIII, a 2.3-cm lesion with strong ar-
terial supply ( a ) and rapid washout ( b ) was 
detected. Note the corona enhancement in 
the portovenous scan ( b ), which is typical 
for HCC. The lesion was diagnosed non-
invasively as HCC based on the EASL-
AASLD criteria. The MR images of the 
same patient are shown in figure 5. 
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differentiation between regenerative nodules, low-grade 
and high-grade dysplastic nodules and well-differentiat-
ed HCC would be desirable. This so-called ‘grey zone of 
hepatocarcinogenesis’ remains still unclear for imaging 
(either with CT or magnetic resonance imaging (MRI)) 
as well as even sometimes for pathology  [13] . MDCT as a 
modality which works based on attenuation differences 
due to a different vascular supply is with current technol-
ogy as well as mere extracellular MRI not able to contrib-
ute to this differential diagnosis with confidence  [14] .
 The detection rates of HCC reported in the literature 
are highly variable. One trial with a very stringent meth-
odology and whole-liver explant correlation showed a 
sensitivity of 61%, a specificity of 66% and a negative pre-
dictive value of 30% for the detection of HCC by means 
of triphasic CT  [14] . A subgroup analysis in this trial re-
vealed a strong influence of the lesion size. While lesions 
 1 2 cm were detected in 100%, lesions  ! 1 cm were only 
detected in 10%  [14] . Another trial with a 4-row MDCT 
demonstrated an overall sensitivity of 73% for HCC de-
tection, with also markedly reduced detection rates (33%) 
for lesions  ! 1 cm  [8] . A recent publication by Maetani et 
al.  [15] exhibited a sensitivity, positive predictive value 
and accuracy for HCC detection by means of MDCT with 
87, 96 and 84%, respectively. Kim et al.  [16] evaluated 
 ferucarbotran-enhanced 3.0-T MRI versus triple-phase 
MDCT and found a superior sensitivity for HCC detec-
tion of 98.1% in MRI versus 92.9% in MDCT. The higher 
sensitivity of MRI was largely attributable to a greater 
ability of the MRI to detect small ( ! 1 cm) HCC (92.6% 
for MRI and 37.0% for MDCT).
 Since CT can only depict the vascularity of lesions, it 
is difficult to distinguish between simple regenerative 
nodules, high-grade dysplastic nodules and early HCC in 
the cirrhotic liver  [13, 14] . The advantages of MRI in this 
respect are the possibility of tissue characterization based 
on different contrast weightings of the pulse sequences 
(T 1 , T 2 ) and the availability of several liver-specific con-
trast agents – as will be pointed out in the following part 
of this article.
 Magnetic Resonance Imaging 
 The evaluation of the cirrhotic liver is a challenging 
task for every imaging modality and this holds also true 
for MRI. However, with MRI the criteria for the evalua-
tion of the focal lesions in cirrhotic liver are expanded 
from vascularity alone to cellular density and tissue com-
position by means of precontrast sequences and diffu-
a b
c d
 Fig. 2. CT scan of a hypovascular HCC in 
a 75-year-old male patient with liver cir-
rhosis Child-Pugh A based on a chronic 
hepatitis B. In liver segment II, a hy-
podense, well-circumscribed round lesion 
(arrow) is seen in plain CT ( a ). In the arte-
rial-dominant phase ( b ), only faint en-
hancement can be delineated, overall the 
lesions remains hypodense in arterial and 
portovenous phase ( c ). The patient under-
went angiography, which also did not re-
veal a hypervascular tumor (not shown 
here). In the plain CT after probatory seg-
mental lipiodol injection (d) during angi-
ography, the lesion still appears hypodense. 
Percutaneous biopsy revealed an undiffer-
entiated HCC (WHO grade 3). The patient 
was treated with radiofrequency ablation. 
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sion-weighted MRI (DWI), to the presence of Kupffer 
cells by means of superparamagnetic particles of iron ox-
ide (SPIO) and to the integrity of hepatocellular function 
and biliary excretion by means of hepatobiliary contrast 
agents ( table 1 ).
 MRI has made dramatic changes with regard to arti-
fact robustness, spatial resolution and speed in the ab-
dominal area. The use of phased-array multichannel coils 
and fast imaging techniques like gradient recalled echo 
(GRE) or fast spin echo (FSE) techniques are now estab-
lished since many years as a standard for abdominal MRI. 
The introduction of parallel imaging, DWI, 3D GRE 
techniques with interpolation and ultrashort repetition 
times and the navigator techniques of respiratory trigger-
ing have been introduced recently and are by now already 
in broad use  [17–19] . A liver MR study usually comprises 
a T 1 w 2D GRE sequence in-phase and opposed-phase, a 
T 2 w single-shot FSE and/or T 2 w multi-shot FSE with fat 
saturation, a DWI echoplanar imaging sequence and a 
dynamic T 1 w 3D GRE sequence with fat saturation after 
contrast agent injection. Depending on the type of con-
trast medium, additional sequences for the liver-specific 
phase are performed, as T 2 *w GRE sequences for SPIO-
enhanced MRI and T 1 w 2D or 3D sequence for hepato-
biliary agents.
 The contrast agents used for liver MRI are on the one 
hand extracellular, unspecific gadolinium agents, and on 
the other, liver-specific contrast agents. The latter can be 
divided into iron-oxide particles (SPIO), which are tar-
geted to the reticuloendothelium system, to the so-called 
Kupffer cells and the hepatobiliary contrast agents, which 
are targeted directly to the hepatocyte and are excreted 
via the bile. There are currently five approved liver-spe-
cific contrast agents with different availabilities on the 
market: ferumoxide (Endorem  , Guerbet, Aulnay-sous-
Bois, France); ferucarbotran (Resovist  , Bayer Schering 
Pharma AG, Berlin, Germany); mangafodipir trisodi-
um/Mn-DPDP (Teslascan  , GE Healthcare Biosciences,
Little Chalfont, UK); gadobenate-dimeglumine/Gd-
BOPTA (MultiHance  , Bracco Imaging, Milan, Italy), 
and  gadoxetic-acid/Gd-EOB-DTPA (Primovist  , Bayer 
Schering Pharma AG, Berlin, Germany).
 Non-enhanced MRI plays an important role in the 
characterization of different tissue components. The sig-
nal intensity of hepatic nodules in the cirrhotic liver can 
vary in T 1 w and T 2 w plain sequences. It has been demon-
strated that copper deposition, glycogen, intratumoral 
bleeding or fat within a nodule causes hyperintensity on 
plain T 1 w sequences  [20] . Since hyperintensity occurs in 
dysplastic nodules as well as in approximately one third 
of moderately differentiated HCC, it seems impossible to 
distinguish the nature of a hepatic nodule based on T 1 w 
signal alone  [21] ( fig. 3 ). For the signal behavior in T 2 w 
sequences, hyperintensity with depiction of a mosaic pat-
tern has been described to be typical for HCC and has 
been seen in 77% of cases  1 3 cm  [21] . In the same evalu-
ation, overall 91% of HCC depicted as hyperintense le-
sions in T 2 w images, whereas the signal intensity in T 1 w 
sequences was quite equally distributed between hypo-, 
iso- and hyperintense  [21] . 6% isointense T 2 w nodules 
represented well-differentiated HCCs (grade 1), all 3% 
hypointense nodules were found to be necrotic HCC  [21] . 
Based on these data, the combination of signal intensity 
on T 1 w and T 2 w images is rendered to be a useful adjunct 
in the differential diagnosis of hepatocellular nodules in 
cirrhotic livers. A nodule that is hyperintense on T 1 w im-
ages and isointense on T 2 w images usually indicates that 
the lesion bears a certain risk for ongoing malignant 
transformation (often high-grade dysplastic nodules or 
early well-differentiated HCC). In contrast, nodules that 
are hyperintense on T 1 w images and iso- or hyperintense 
on T 2 w images usually represent an overt HCC  [22] 
Table 1. Key features of regenerative nodules, dysplastic nodules 
and HCCs in MRI
Regenerative
nodules
Dysplastic
nodules
Overt HCCs
Plain MRI
T1w 2D GRE = d f or d
T2w FSE fs = or f = or f d
Early dynamic phase
Arterial phase no
enhancement
no
enhancement
arterial
enhance-
ment
Portovenous/
delayed phase
no
washout
no
washout
venous
washout
Liver-specific phase
SPIO = or f = d
Hepatobiliary
agents = f or d f
This table summarizes the most important and typical MRI 
findings in regenerative nodules, dysplastic nodules and HCCs. 
However, this table is not able to express the complexity of all 
kinds of borderline lesions (e.g. high-grade dysplastic nodule vs. 
early HCC) and does not consider atypical or infrequent imaging 
findings (like hepatobiliary accumulation in well-differentiated 
HCC or hypovascular HCC).
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( fig. 3 c, d). A nodule being isointense on T 1 w images and 
hypo- or isointense on T 2 w images exhibits the typical 
signal behavior of a regenerative nodule  [23] ( fig. 4 ). Oth-
er typical morphological features of HCC that can be
seen on precontrast (and contrast-enhanced) MR images 
include a pseudocapsule  [24] and a mosaic pattern  [21, 
25] .
 DWI has long played only a minor role in abdominal 
imaging; however, with new scanner generations with 
homogenous magnetic fields and with the introduction 
of parallel imaging, DWI with echoplanar images is fea-
sible with a high image quality and robustness  [26, 27] . 
DWI can help to increase the detection rate of focal liver 
lesions, especially due to the black-blood effect, which 
helps to perceive even very small lesions or lesions di-
rectly adjacent to vessels easily and fast  [27] . A recent 
study that focused on the added value of DWI in the cir-
rhotic liver showed that the detection rate for HCC was 
increased from 83–85 to 98% in a two-reader analysis of 
gadolinium-enhanced images only and gadolinium-en-
hanced + DWI images  [28] . Moreover, the quantification 
of restricted diffusion with the apparent diffusion coef-
ficient helps to differentiate between benign and malig-
nant lesions  [26] . However, up to now there is no evidence 
in the literature in how far DWI might be a feasible ap-
proach to differentiate between regenerative nodules, 
dysplastic nodules and HCC. Another interesting appli-
cation for DWI in the cirrhotic liver is the quantification 
of liver fibrosis in chronic hepatitis, which shows very 
promising results in the literature  [29] .
 The dynamic MR examination with gadolinium-
based contrast agents provides information on the chang-
es of vascular supply within different hepatic nodules in 
the cirrhotic liver and is a crucial part of the evaluation 
of patients with suspected HCC ( fig. 5 ). With regard to 
the criteria for the diagnosis of overt HCC, the same con-
trast agent behavior as described for CT is used for MRI, 
which means hypervascularity in the arterial-dominant 
phase and pathological washout in the portovenous or 
delayed phase. Gadolinium-enhanced MRI with T 1 w 3D 
GRE sequences, allowing for thin slices, enables detec-
tion of HCC nodules with 76% sensitivity, 75% specificity 
and a negative predictive value of 50%  [14] . The reported 
values of Burrel et al.  [14] may seem only moderate; how-
ever, it has to be taken into account that they were vali-
dated against whole-liver explant specimens and that a 
a b
c d
 Fig. 3. Plain MR scans of two different pa-
tients with liver cirrhosis. In the upper row 
( a ,  b ), a nodule is depicted which exhibits 
hyperintensity in the plain T 1 w 2D GRE 
sequence in-phase ( a ), and hypointensity 
in the plain T 2 w FSE with fat saturation 
( b ). No pathological vascularization was 
depicted (not shown here). Based on fol-
low-up the nodule was diagnosed as a re-
generative nodule. The nodule in the lower 
row ( c ,  d ) is also depicted with hyperinten-
sity in the T 1 w scan ( c ), but already the size 
of the lesion and the pseudocapsule raise 
suspicion. This nodule appears hyperin-
tense on the T 2 w image ( d ) with a mosaic 
pattern. The histological diagnosis of the 
nodule is HCC (same lesions as shown in 
fig.  2). 
 Imaging of HCC by CT and MRI:
State of the Art 
Dig Dis 2009;27:114–124 119
large number of small lesions ( ! 2 cm) were included. 
Overall, MRI showed superior results to spiral CT in the 
detection of HCC in this study (sensitivity 76% MRI vs. 
61% CT). For HCC  1 2 cm, MRI and CT showed a detec-
tion rate of 100%, for HCC between 1 and 2 cm MRI and 
CT showed a detection rate of 89 and 65% (p = 0.03), re-
spectively, and for HCC  ! 1 cm values of 34 and 10% (p = 
0.06) were seen, respectively. Beside the clear superiority 
of MRI versus CT for the detection of HCC in the con-
trast-enhanced dynamic phase examination, these data 
show that the real challenge for the future and for new 
techniques will be to increase the detection rate for very 
small HCC nodules. These results are supported by 
Lauenstein et al.  [30] who found an overall detection rate 
for HCC with gadolinium-enhanced 3D GRE sequences 
of 77.8% ( 1 2 cm 100%,  ! 2 cm 55.6%). In various other 
trials, ultrasound, biphasic spiral CT and MRI were com-
pared and MRI proved to be superior to the other mo-
dalities in the detection of HCC  [31–34] . Beside the high-
er detection rate of MRI, it is also considered to be more 
specific with less false-positive lesions than CT in the dif-
ferentiation between HCC and regenerative nodules  [14, 
35] . This can be explained by the additional diagnostic 
criteria (e.g. T 2 w signal intensity) for the diagnosis of 
HCC in MRI ( fig. 6 ). In this respect the results of Holland 
et al.  [36] are interesting; they evaluated lesions seen only 
on arterial phase images (isointense in T 2 w images, no 
washout) and found that 93% were not HCC at histology. 
Therefore, the interpretation of hypervascular lesions in 
the cirrhotic liver has to include also plain MR signal be-
havior and the washout kinetics.
 The use of liver-specific contrast agents aims to in-
crease the sensitivity and specificity of MRI in the cir-
rhotic liver. With regard to the question whether gado-
linium-enhanced MRI or SPIO-enhanced MRI as stand-
alone technologies are superior for HCC detection, the 
reports in the literature clearly indicate that for detection 
a gadolinium-enhanced T 1 w dynamic examination re-
a b c
d e f
 Fig. 4. MR scan of a 45-year-old female patient with liver cirrhosis 
due to chronic hepatitis C. The patient suffers from overt HCC 
(not shown here). Additionally, two nodules were detected in seg-
ment IVb (small arrow) and in segment III (broad arrow). The 
nodule in segment IVb is slightly hyperintense in the T 1 w 3D GRE 
with fat saturation ( a ) and T 1 w 2D GRE without fat saturation ( b ) 
and isointense in the T 2 w FSE sequence ( c ). In the T 1 w 3D GRE 
sequence after Gd-EOB-DTPA injection (d), no hypervascularity 
can be seen in the arterial phase (considering the precontrast sig-
nal); however, the nodule displays faint washout in the portove-
nous scan ( e ) and decreased hepatobiliary enhancement in the 
liver-specific phase 20 min after injection ( f ). This pattern is com-
patible with a high-grade dysplastic nodule. On the other hand, 
the smaller nodule in segment III is nearly isointense in the T 1 w 
images ( a ,  b ) and hypointense in the T 2 w FSE sequence ( c ). In the 
arterial phase no hypervascularity can be seen and no washout in 
the portovenous scan ( e ). There is some accumulation of contrast 
agent in the liver-specific phase. This pattern is compatible with 
a normal regenerative nodule. Due to the dysplastic nodule in seg-
ment III, the patient is in close follow-up; since 9 months both le-
sions are unchanged. 
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mains the method of choice. In a study by Kim et al.  [37] 
superiority of gadolinium-enhanced MRI over SPIO MRI 
(91.3 vs. 77.3%, respectively) was demonstrated. On the 
other hand, severe liver cirrhosis with extensive fibrosis 
may lead to an overestimation of tumor extension in 
SPIO-enhanced MRI since fibrotic areas do not take up 
SPIO so that differentiation from HCC nodules may be 
difficult. SPIO-enhanced MRI helps to differentiate be-
tween regenerative nodules, dysplastic nodules and overt 
HCC based on the different degree of iron uptake  [38–
41] . Nevertheless, it has been shown that well-differenti-
ated HCC can contain a considerable amount of Kupffer 
cells  [40] . The high contrast between liver parenchyma 
and HCC in SPIO-enhanced MRI is particularly helpful 
a b
c d
 Fig. 5. MR scan of a 62-year-old female pa-
tient with liver cirrhosis Child-Pugh A 
based on a chronic hepatitis C. T 1 w GRE 
sequence with fat saturation in arterial ( a ), 
portovenous ( b ) and equilibrium phase ( c ) 
after bolus injection of Gd-EOB-DTPA;
 d shows the liver-specific phase 20 min af-
ter injection. Note the lesion (arrow) with 
the typical enhancement pattern of a HCC 
with arterial hypervascularity and rapid 
washout, which can be appreciated best in 
the equilibrium phase scan ( c ). As an ad-
ditional criterion for a HCC, missing hep-
atobiliary uptake with high tumor-to-liver 
contrast is seen in the liver-specific phase 
( d ). Note multiple small nodules ( ! 5 mm) 
with hepatobiliary uptake representing 
 regenerative nodules. The corresponding 
CT images are shown in figure 1. 
a b c
d e f
 Fig. 6. A 44-year-old male patient with a 
history of alcohol-induced liver cirrhosis 
and two HCC nodules (arrows). Gd-EOB-
DTPA-enhanced MRI ( a ,  b ) and CT ( d ,  e ) 
images in arterial and portovenous phase. 
Note the superior visualization of arterial 
hypervascularization and especially the 
better depiction of the washout in MRI ( b ) 
versus CT ( e ). Moreover, with MRI, addi-
tional criteria like the liver-specific phase 
showing missing hepatobiliary uptake ( c ) 
and diffusion-weighted images ( f ) allow a 
fast and easy detection of lesions. 
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for the evaluation of the tumor burden of the liver in case 
of the diffuse growth pattern of HCC. However, it is more 
or less accepted that evaluation of HCC without a multi-
phasic dynamic examination (either MDCT or gadolini-
um-enhanced MRI) is not sufficient since the assessment 
of pathological vascularity is still the main diagnostic cri-
terion for HCC. Therefore, the combination of both SPIO 
and gadolinium contrast agents in one MR examination 
(so-called double-contrast technique) is considered as 
very useful  [39, 42, 43] . In a recent study the detection rate 
and Az value of non-invasive double-contrast MRI was 
with 93 and 0.96%, respectively, similar to combined 
CTAP/CTHA  [44] . However, double-contrast MRI is off-
label use and it is a time-consuming examination with 
the need of two contrast agent injections ( fig. 7 ).
 With Mn-DPDP, HCC can typically be depicted as a 
hypointense lesion in the delayed-phase images. Mn-
DPDP showed promising results with regard to the HCC 
detection. A study by Bartolozzi et al.  [45] showed a detec-
tion rate of 86% for HCC, which was in this study slightly 
higher than with biphasic spiral CT (80%, n.s.). Moreover, 
Mn-DPDP provides an additional criterion for the char-
acterization of the different nodules in the cirrhotic liver 
 [46] . However, because Mn-DPDP is not recommended 
for bolus injection, a second contrast agent has to be ad-
ministered for the evaluation of the vascularity so that 
(like in double-contrast MRI) additional examination 
time and two contrast agent injections are needed. The 
two hepatobiliary contrast agents with also extracellular 
properties, Gd-BOPTA and Gd-EOB-DTPA, do not suf-
fer from this limitation. They can be injected as a bolus 
and provide both a sufficient vascular phase as well as a 
hepatobiliary phase  [47–49] . Their main difference is the 
dosing of gadolinium (Gd-EOB-DTPA: 0.025 mmol/kg 
b.w. compared to Gd-BOPTA 0.05 mmol/kg b.w.) and the 
higher amount of liver-specific uptake of Gd-EOB-DTPA 
(50 vs. 5%) compared to Gd-BOPTA  [48] . In a study by 
Kim et al.  [44] , Gd-BOPTA dynamic imaging (without 
delayed-phase imaging) yielded a mean sensitivity and 
positive predictive value of 91.3 and 89.2%, respectively. 
A quite recent study with Gd-BOPTA showed excellent 
results for the detection of HCC up to values of 87% sen-
sitivity and 79% specificity with a protocol including pre-
contrast, early dynamic and 1-hour delayed images  [50] . 
For the setting of the HCC and cirrhotic liver, little is 
known about the added value of the delayed phase for tu-
mor detection – in contrast to metastases, where an in-
creased detection rate was clearly documented with help 
of delayed-phase images  [51] . Several reports have been 
published showing that missing hepatobiliary uptake of 
Gd-BOPTA is an additional criterion for HCC, especially 
in contrast to regenerative nodules  [52–54] . Gd-EOB-
DTPA was approved in many countries worldwide be-
tween 2005 and 2008. Up to now there is still limited in-
formation about Gd-EOB-DTPA MRI in the cirrhotic liv-
er. For a general population, Gd-EOB-DTPA showed 
(similar to Gd-BOPTA) an increased detection rate for 
malignant liver lesions compared to MDCT  [55, 56] . In 
the hepatobiliary phase of Gd-EOB-DTPA, almost all 
HCCs and some dysplastic nodules depict as an area of 
a b
 Fig. 7. A 56-year-old male patient with chronic hepatitis B and 
liver cirrhosis. Double-contrast MRI with a gadolinium-en-
hanced arterial phase T 1 w 3D GRE sequence ( a ) and a SPIO-en-
hanced T 2 w GRE sequence ( b ). Note the hypervascular spot (tri-
angle) within the only slightly hyperenhancing nodule (arrow). 
The hypervascular spot returned to isointensity on portovenous 
phase images (not shown) and exhibits clearly missing SPIO up-
take in the liver-specific phase ( b ), whereas the surrounding nod-
ule shows preserved SPIO uptake. This lesion shows the so-called 
nodule-in-nodule appearance, representing an overt HCC (with 
typical vascular changes and missing SPIO uptake) which aroused 
in the surrounding regenerative nodule. 
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decreased liver-specific uptake resulting in hypointense 
lesions  [57] . The early dynamic phase of Gd-EOB-DTPA 
was questioned due to the lower dosing of gadolinium; 
however, several reports documented that a sufficient ar-
terial phase can be acquired and that hypervascular tu-
mors can be depicted accurately  [58, 59] . However, due to 
the smaller injection volume it is recommended to use a 
bolus timing technique for Gd-EOB-DTPA-enhanced 
MRI, and there is data suggesting that a slower injection 
rate can lead to a more robust arterial phase with even 
increased arterial enhancement  [60, 61] . First emerging 
data from abstracts show promising results for Gd-EOB-
DTPA in the detection of HCC  [62, 63] . Also, the added 
value of the 20-min hepatobiliary-phase images has been 
documented by first abstracts. Lee et al.  [64] demonstrat-
ed an increased rate of correctly diagnosed HCC from 
65.2% for MDCT, 80.3% for early dynamic Gd-EOB-
DTPA, and 83.3% for combined dynamic and 20-min 
hepatobiliary phase. In this study, 93.4% of HCCs showed 
to by hypointense in the hepatobiliary phase.
 For all three hepatobiliary contrast agents, liver-spe-
cific uptake in malignant HCCs with depiction as hyper-
intense lesions in the liver-specific phase has been dem-
onstrated, but usually the frequency of this finding is low 
( ! 5%) and confined to well-differentiated HCCs  [52, 57, 
64, 65] . Generally, the presence of typical changes of the 
vascular supply will help to correctly characterize these 
lesions. Up to now, no exact thresholds for the uptake of 
regenerative nodules, dysplastic nodules and HCCs have 
been defined. However, the potential value of showing 
impaired biliary uptake for the evaluation of nodules in 
the cirrhotic liver has been appreciated by several authors 
 [13, 66, 67] . In this respect it has been pointed out that 
hepatobiliary MRI helps to detect hepatic nodules ‘at risk’ 
for transformation into well-differentiated HCC (e.g. 
high-grade dysplastic nodules) prior to neovasculariza-
tion and prior to development of overt HCC  [13, 57] . That 
implicates that in the future, for example nodules with 
features of a high-grade dysplasia at precontrast MRI 
(T 1 w hyperintense, T 2 w iso- or hyperintense) and with 
hypointense depiction in hepatobiliary-phase images 
might be considered as HCC from a certain size on even 
with missing neovascularization – helping to overcome 
the diagnostic gap which exists in hypovascular HCC 
 [68] . However, such an approach still needs more data on 
large patient cohorts.
 Conclusion 
 Although MDCT has reached a high standard for the 
detection of HCC with the possibility of multiphasic ex-
aminations and high-resolution isotropic datasets, MRI 
has to be regarded as the best non-invasive imaging mo-
dality for the detection of HCC and for the characteriza-
tion of nodules in patients with liver cirrhosis. The mul-
tiple criteria (signal intensity precontrast, morphological 
features, early dynamic contrast-enhanced MRI, and es-
pecially liver-specific contrast agents) available with MRI 
result in a unique imaging modality enabling a very high 
diagnostic standard for the evaluation of the cirrhotic 
 liver. However, it has to be recognized for all imaging 
 modalities that there is a diagnostic problem for lesions 
 ! 1 cm (in the detection of these small HCC as well as in 
the differentiation from other non-neoplastic nodules). 
With regard to the guidelines by the EASL-AASLD  [12] , 
vascularity of lesions in the cirrhotic liver is still the main 
criterion; however, there is already good evidence that 
liver-specific contrast agents help to increase the detec-
tion rate and might overcome the diagnostic gap of hypo-
vascular HCC. In this respect, larger prospective trials 
are wanted.
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